A new independent 57 page research with title ‘Tyrosine Protein Kinase Mer {Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1} – Pipeline Review, H2 2017’ guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like United States, Europe, Japan, China, India, Others and important players/vendors such as Basilea Pharmaceutica Ltd, Celldex Therapeutics Inc, Celon Pharma SA, Dong-A Socio Holdings Co Ltd, Elsalys Biotech SAS, Ignyta Inc With n-number of tables and figures examining the Tyrosine Protein Kinase Mer the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022
Request a sample report @ https://www.htfmarketreport.com/sample-report/872054-tyrosine-protein-kinase-mer-proto-oncogene-c-mer-or-receptor-tyrosine-kinase-mertk-or-mertk-or-ec-2-7-10-1-pipeline-review
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) – Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
The report ‘Tyrosine Protein Kinase Mer – Pipeline Review, H2 2017’ outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 12 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Glioblastoma Multiforme (GBM), Ovarian Cancer, Astrocytoma, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Esophageal Cancer, Gastric Cancer, Leukemias, Metastatic Colorectal Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinitis Pigmentosa (Retinitis) and Solid Tumor.
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/872054-tyrosine-protein-kinase-mer-proto-oncogene-c-mer-or-receptor-tyrosine-kinase-mertk-or-mertk-or-ec-2-7-10-1-pipeline-review
Scope
– The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
– The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
– The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics
Place a Purchase Order for this Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=872054
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned in the Report
Basilea Pharmaceutica Ltd
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Elsalys Biotech SAS
Ignyta Inc
Ono Pharmaceutical Co Ltd
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) – Overview
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) – Companies Involved in Therapeutics Development
Ba
….Continued
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/872054-tyrosine-protein-kinase-mer-proto-oncogene-c-mer-or-receptor-tyrosine-kinase-mertk-or-mertk-or-ec-2-7-10-1-pipeline-review
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218